Back to Studies


Phase I Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Neonates at Risk of Acquiring HIV-1 Infection

Study Status

Participants Off Study and Primary Analysis Completed

DAIDS Number


IND Number


Clinical Trials Link


IMPAACT 2007 is a Phase I, multi-center, study of HIV-1-exposed infants born to HIV-1-infected mothers. The study is designed to compare the overall safety and pharmacokinetics of Maraviroc solution given during the first six weeks of life to infants born to HIV-1-infected mothers with ARV prophylaxis with two sequential dosing cohorts stratified by maternal use of efavirenz.

Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...